Advertisement

Topics

Neoantigen-primed Dendritic Cells (DC)- Pre-activated T (PreT) Cell Therapy for Refractory Non-small Cell Lung Cancer

2016-11-08 09:23:22 | BioPortfolio

Summary

The study is aimed to the test the efficacy and safety of neoantigen-primed T cell therapy for refractory non-small cell lung cancer.

Description

Patients with pathological confirmed non-small cell lung cancer with no standard treatment are enrolled. The patients fails in previous at least 2 lines of chemotherapy and 1 line of targeted therapy where applicable. This is a prospective exploratory trial. Patients' rebiopsy tumor tissues are subsequent to whole exosome sequencing and possible neoantigens are identified. DC is in vitro primed with synthesized peptides. Patients are treated with DC-primed T cells. Both adverse events and responses are recorded.

Study Design

Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Conditions

Carcinoma, Non-Small-Cell Lung

Intervention

T cells

Location

China West Hospital
Chengdu
Sichuan
China
610000

Status

Not yet recruiting

Source

Sichuan University

Results (where available)

View Results

Links

Published on BioPortfolio: 2016-11-08T09:23:22-0500

Clinical Trials [6852 Associated Clinical Trials listed on BioPortfolio]

Pharmacogenomic Study Realized on "Non-small Cell Lung Carcinoma"

The purpose of this study is to correlate molecular genetic profile with response to chemotherapy in case of primary chemotherapy treatment for non-small cells lung carcinoma.

ABR-217620 in Patients With Advanced Non-Small Cell Lung Cancer, Renal Clear Cell Carcinoma or Pancreatic Cancer

The drug ABR-217620 is a combination of two proteins, one that recognizes tumor cells and one that triggers an attack on the tumor cells by activating some white blood cells belonging to t...

Use of [18]F-FDG on PET/CT as an Alternative Non-invasive Method for Staging of Lung Cancer

To evaluate the diagnostic accuracy of the 18Fluor-fluorodeoxyglucose ([18F]FDG) in the Positron Emission Tomography/Computed Tomography (PET/CT) as compared to mediastinoscopy for staging...

Gene Mutations in Non-Small Cell Lung Cancer Cells

To compare the frequency of individual genetic abnormality between tumor cells and blood specimens.

Metabolomic Analysis of Lung Cancer

The purpose of this study is to learn more about the metabolic properties of cancer cells of patients undergoing surgical removal of small cell and non-small cell lung cancer.

PubMed Articles [33154 Associated PubMed Articles listed on BioPortfolio]

Combined small cell carcinoma of the lung: Is it a single entity?

Small-cell lung carcinoma (SCLC) accounts for 15-20% of all lung cancers, with combined SCLC (CSCLC) comprising 2-5%. Little is known about the clinical characteristics and molecular changes associate...

miR-339-5p downregulation contributes to Taxol resistance in small-cell lung cancer by targeting α1,2-fucosyltransferase 1.

Lung cancer is a leading cause of cancer-related mortality, and non-small-cell lung carcinoma is responsible for almost 80% of lung cancer-related deaths. In recent years, lung cancer has shown increa...

MiR-93-5p up-regulation is involved in non-small cell lung cancer cells proliferation and migration and poor prognosis.

MicroRNA-93-5p (miR-93-5p) dysregulation has been reported in many types of human cancer. However, the collective effect of miR-93-5p in both lung adenocarcinoma and squamous cell carcinoma and the me...

Programmed death-ligand 1 expression in non-small cell lung carcinoma: Comparison among cytology, small biopsy, and surgical resection specimens.

One immunotherapeutic agent for patients with advanced non-small cell lung carcinoma, pembrolizumab, has a companion immunohistochemistry (IHC)-based assay that predicts response by quantifying progra...

The option value of innovative treatments for non-small cell lung cancer and renal cell carcinoma.

To develop a model of the option value a therapy provides by enabling patients to live to see subsequent innovations and to apply the model to the case of nivolumab in renal cell carcinoma (RCC) and n...

Medical and Biotech [MESH] Definitions

A form of highly malignant lung cancer that is composed of small ovoid cells (SMALL CELL CARCINOMA).

Malignant neoplasm arising from the epithelium of the BRONCHI. It represents a large group of epithelial lung malignancies which can be divided into two clinical groups: SMALL CELL LUNG CANCER and NON-SMALL-CELL LUNG CARCINOMA.

A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy.

An anaplastic, highly malignant, and usually bronchogenic carcinoma composed of small ovoid cells with scanty neoplasm. It is characterized by a dominant, deeply basophilic nucleus, and absent or indistinct nucleoli. (From Stedman, 25th ed; Holland et al., Cancer Medicine, 3d ed, p1286-7)

A heterogeneous group of sporadic or hereditary carcinoma derived from cells of the KIDNEYS. There are several subtypes including the clear cells, the papillary, the chromophobe, the collecting duct, the spindle cells (sarcomatoid), or mixed cell-type carcinoma.

More From BioPortfolio on "Neoantigen-primed Dendritic Cells (DC)- Pre-activated T (PreT) Cell Therapy for Refractory Non-small Cell Lung Cancer"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Gilotrif (afatinib)
GILOTRIF (afatinib) is a kinase inhibitor indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L8...

DNA sequencing
DNA sequencing is the process of determining the precise order of nucleotides within a DNA molecule. During DNA sequencing, the bases of a small fragment of DNA are sequentially identified from signals emitted as each fragment is re-synthesized from a ...


Searches Linking to this Trial